Johnson Matthey PLC (LON:JMAT - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,417.35 ($19.37) and traded as high as GBX 1,717 ($23.46). Johnson Matthey shares last traded at GBX 1,708 ($23.34), with a volume of 348,658 shares.
Johnson Matthey Stock Performance
The company has a debt-to-equity ratio of 62.73, a current ratio of 1.45 and a quick ratio of 0.76. The company's fifty day simple moving average is GBX 1,510.05 and its two-hundred day simple moving average is GBX 1,417.35. The stock has a market cap of £2.86 billion, a price-to-earnings ratio of 29.02, a P/E/G ratio of 49,242.50 and a beta of 0.95.
Johnson Matthey (LON:JMAT - Get Free Report) last released its quarterly earnings data on Thursday, May 22nd. The company reported GBX 149.20 ($2.04) earnings per share for the quarter. Johnson Matthey had a net margin of 0.84% and a return on equity of 4.49%. On average, analysts forecast that Johnson Matthey PLC will post 173.4112903 earnings per share for the current year.
Johnson Matthey Increases Dividend
The firm also recently disclosed a dividend, which was paid on Wednesday, April 16th. Shareholders of record on Thursday, April 10th were issued a dividend of GBX 32 ($0.44) per share. This is an increase from Johnson Matthey's previous dividend of $22.00. The ex-dividend date was Thursday, April 10th. This represents a yield of 1.88%. Johnson Matthey's dividend payout ratio is presently 130.84%.
Insiders Place Their Bets
In other news, insider Liam Condon bought 30 shares of Johnson Matthey stock in a transaction dated Wednesday, April 16th. The stock was purchased at an average price of GBX 1,200 ($16.40) per share, for a total transaction of £360 ($491.87). Over the last 90 days, insiders have acquired 62 shares of company stock worth $84,978. Insiders own 0.61% of the company's stock.
Johnson Matthey Company Profile
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
